Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Content versus Label Claims in Cannabidiol (CBD)-Containing Products Obtained from Commercial Outlets in the State of Mississippi
Bill J. Gurley, Timothy F. Murphy, Waseem Gul, et al.
Journal of Dietary Supplements (2020) Vol. 17, Iss. 5, pp. 599-607
Closed Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

Therapeutic Efficacy of Cannabidiol (CBD): a Review of the Evidence From Clinical Trials and Human Laboratory Studies
Dennis J. Sholler, Lauren Schoene, Tory R. Spindle
Current Addiction Reports (2020) Vol. 7, Iss. 3, pp. 405-412
Open Access | Times Cited: 102
Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners
Owen S. Miller, Edmund J. Elder, Karen J. Jones, et al.
Epilepsy & Behavior (2022) Vol. 127, pp. 108514-108514
Closed Access | Times Cited: 46
Evaluation of dispensaries’ cannabis flowers for accuracy of labeling of cannabinoids content
Mona M. Geweda, Chandrani G. Majumdar, Malorie N Moore, et al.
Journal of Cannabis Research (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 11
Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples
Barry E. Gidal, Ryan G. Vandrey, Chela Wallin, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 11
Validated LC-MS/MS methodology for the quantification of CBD, trace level THCA and UK controlled cannabinoids (Δ9THC, Δ8THC, CBN and THCV) in food samples
Tabatha Hambidge, Ralph G. Nash, Steve Corless, et al.
Analytical Methods (2025)
Open Access | Times Cited: 1
Evaluation of cannabidiol-based products in Brazil: how can current regulations influence their labeling quality?
Andréa Donatti Gallassi, André Wagner Carvalho de Oliveira, Nathália Silva Mendes, et al.
Journal of Cannabis Research (2025) Vol. 7, Iss. 1
Open Access | Times Cited: 1
The Pharmacokinetics and Pharmacodynamics of a Hemp-Derived “Full-Spectrum” Oral Cannabinoid Product with a 1:1 Ratio of Cannabidiol to Cannabidiolic Acid and Delta-9-Tetrahydrocannabinol to Delta-9-Tetrahydrocannabinolic Acid: A Double-Blind, Placebo-Controlled, Within-Subjects Human Laboratory Study
Harrison Elder, C. Austin Zamarripa, Mitchell Klausner, et al.
Cannabis and Cannabinoid Research (2025)
Closed Access | Times Cited: 1
Cannabis Contaminants Limit Pharmacological Use of Cannabidiol
Zackary T. Montoya, Matthieu Conroy, Brian D. Vanden Heuvel, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 54
Cannabidiol Use for Fibromyalgia: Prevalence of Use and Perceptions of Effectiveness in a Large Online Survey
Kevin F. Boehnke, Joel Gagnier, Lynne Matallana, et al.
Journal of Pain (2021) Vol. 22, Iss. 5, pp. 556-566
Open Access | Times Cited: 46
A Coala‐T‐Cannabis Survey Study of breast cancer patients' use of cannabis before, during, and after treatment
Marisa C. Weiss, Julianne Hibbs, Meghan Buckley, et al.
Cancer (2021) Vol. 128, Iss. 1, pp. 160-168
Open Access | Times Cited: 44
Cannabidiol (CBD) product contamination: Quantitative analysis of Δ9-tetrahydrocannabinol (Δ9-THC) concentrations found in commercially available CBD products
Erin M. Johnson, Michael Kilgore, Shanna Babalonis
Drug and Alcohol Dependence (2022) Vol. 237, pp. 109522-109522
Open Access | Times Cited: 35
Label accuracy of unregulated cannabidiol (CBD) products: measured concentration vs. label claim
Erin M. Johnson, Michael Kilgore, Shanna Babalonis
Journal of Cannabis Research (2022) Vol. 4, Iss. 1
Open Access | Times Cited: 35
Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex
Robert T. Wechsler, David E. Burdette, Barry E. Gidal, et al.
Epilepsia Open (2024) Vol. 9, Iss. 5, pp. 1632-1642
Open Access | Times Cited: 7
Emerging challenges in the extraction, analysis and bioanalysis of cannabidiol and related compounds
Virginia Brighenti, Michele Protti, Lisa Anceschi, et al.
Journal of Pharmaceutical and Biomedical Analysis (2020) Vol. 192, pp. 113633-113633
Closed Access | Times Cited: 49
Hepatotoxicity due to herbal dietary supplements: Past, present and the future
Bill J. Gurley, Mitchell R. McGill, Igor Koturbash
Food and Chemical Toxicology (2022) Vol. 169, pp. 113445-113445
Open Access | Times Cited: 24
High Prevalence of Cannabidiol Use Within Male Professional Rugby Union and League Players: A Quest for Pain Relief and Enhanced Recovery
Andreas Kasper, S. Andy Sparks, Matthew P. Hooks, et al.
International Journal of Sport Nutrition and Exercise Metabolism (2020) Vol. 30, Iss. 5, pp. 315-322
Open Access | Times Cited: 34
Pharmacokinetic Profile of ∆9-Tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Products
Cecilia L. Bergeria, Tory R. Spindle, Edward J. Cone, et al.
Journal of Analytical Toxicology (2022) Vol. 46, Iss. 6, pp. 583-591
Open Access | Times Cited: 21
Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain)
Kevin F. Boehnke, Winfried Häuser, Mary‐Ann Fitzcharles
Current Rheumatology Reports (2022) Vol. 24, Iss. 7, pp. 238-246
Open Access | Times Cited: 20
The analysis of cannabinoids in e-cigarette liquids using LC-HRAM-MS and LC-UV
Sophia Barhdadi, P. Courselle, Eric Deconinck, et al.
Journal of Pharmaceutical and Biomedical Analysis (2023) Vol. 230, pp. 115394-115394
Closed Access | Times Cited: 11
Commercial Delta-8 THC Products: an Analysis of Content and Labeling
Eric E. Kaczor, Kevin Greene, Kavita M. Babu, et al.
Journal of Medical Toxicology (2023) Vol. 20, Iss. 1, pp. 31-38
Closed Access | Times Cited: 11
Cannabis and Athletic Performance
Jamie F. Burr, Christian P. Cheung, Andreas Kasper, et al.
Sports Medicine (2021) Vol. 51, Iss. S1, pp. 75-87
Open Access | Times Cited: 24
On offer to Ontario consumers three years after legalization: A profile of cannabis products, cannabinoid content, plant type, and prices
Felicia Tassone, Patricia Di Ciano, Yuxin Liu, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 10
An Overview of Cannabidiol
Alexandra Sideris, Lisa Doan
Anesthesia & Analgesia (2023) Vol. 138, Iss. 1, pp. 54-68
Open Access | Times Cited: 9
Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products
Edward Chesney, Philip McGuire, Tom P. Freeman, et al.
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 26
Cannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia
Kevin F. Boehnke, Joel Gagnier, Lynne Matallana, et al.
Journal of Pain (2021) Vol. 23, Iss. 1, pp. 45-54
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top